Bio-Rad Laboratories Class A
483 hedge funds and large institutions have $6.06B invested in Bio-Rad Laboratories Class A in 2023 Q4 according to their latest regulatory filings, with 87 funds opening new positions, 165 increasing their positions, 171 reducing their positions, and 64 closing their positions.
66% more call options, than puts
Call options by funds: $47.3M | Put options by funds: $28.5M
36% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 64
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
3% more funds holding
Funds holding: 467 → 483 (+16)
0.2% less ownership
Funds ownership: 78.26% → 78.06% (-0.2%)
4% less repeat investments, than reductions
Existing positions increased: 165 | Existing positions reduced: 171
10% less capital invested
Capital invested by funds: $6.73B → $6.06B (-$668M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$89.7M |
| 2 |
PCM
Parsifal Capital Management
Greenwich,
Connecticut
|
+$60.1M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$53M |
| 4 |
SHCM
Sachem Head Capital Management
New York
|
+$49.1M |
| 5 |
Select Equity Group
New York
|
+$42.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Brown Advisory
Baltimore,
Maryland
|
-$295M |
| 2 |
HRCM
Hawk Ridge Capital Management
Los Angeles,
California
|
-$76.8M |
| 3 |
Millennium Management
New York
|
-$48.1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$37.4M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$36.1M |
BIO Hedge Fund Activity: Q4 2023 in Review
483 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q4 2023, worth a combined $6.06B — down 9.9% from $6.73B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new BIO positions and 64 closed out — a net gain of 23 holders — while 165 added to existing stakes and 171 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $89.7M. The largest seller was Brown Advisory, cutting an estimated $295M.
- 483 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q4 2023, up from 467 in Q3 2023.
- Funds reported $6.06B of Bio-Rad Laboratories Class A stock for Q4 2023, down 9.9% quarter-over-quarter.
- 87 funds opened new Bio-Rad Laboratories Class A positions in Q4 2023 and 64 closed out, a net change of +23 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q4 2023 was Morgan Stanley, an estimated $89.7M added.
- The largest Bio-Rad Laboratories Class A seller in Q4 2023 was Brown Advisory, an estimated $295M sold.
Based on aggregated 13F filings for Q4 2023.